Karen E. Knudsen, PhD

Contact Dr. Knudsen

Sidney Kimmel Cancer Center
233 South 10th Street
BLSB 1050
Philadelphia, PA 19107

(215) 503-5692

Most Recent Peer-reviewed Publications

  1. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
  2. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy
  3. Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer
  4. Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset
  5. DNA damage response in prostate cancer
  6. PARP-1 regulates DNA repair factor availability
  7. Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))
  8. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells
  9. MAPK Reliance via acquired CDK4/6 inhibitor resistance in cancer
  10. A patient-derived explant (PDE) model of hormone-dependent cancer
  11. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import
  12. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
  13. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  14. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012
  15. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non–small cell lung cancer
  16. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  17. Differential impact of RB status on E2F1 reprogramming in human cancer
  18. Prostate cancer genomic analysis: Routine or research only?: Limitations exist for guiding therapeutic treatment
  19. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  20. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells